Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thiamiprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 known ✓ | Q16531 | 10/20 | 0.42 |
| ▸ | CRBN known ✓ | Q96SW2 | 10/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azathioprine SCHEMBL28086576 | 0.81 | MAPT (0.64) | CYP1A2DDB1CRBNALDH1A1IKZF3 | |
| Azathioprine SCHEMBL3261116 | 0.69 | MAPT (0.68) | CYP1A2ALDH1A1TDP1HTTHBB | |
| Thiamiprine SCHEMBL4851 | 0.66 | MAPT (0.71) | CYP1A2ALDH1A1TDP1HTTHBB | |
| Thalidomide SCHEMBL15197560 | 0.65 | CRBN (1.00) | CYP1A2DDB1CRBNALDH1A1IKZF3 | |
| Thalidomide SCHEMBL571278 | 0.65 | CRBN (1.00) | CYP1A2DDB1CRBNALDH1A1IKZF3 | |
| Thalidomide SCHEMBL410642 | 0.65 | CRBN (1.00) | CYP1A2DDB1CRBNALDH1A1IKZF3 | |
| Thalidomide SCHEMBL455269 | 0.65 | CRBN (1.00) | CYP1A2DDB1CRBNALDH1A1IKZF3 | |
| Thalidomide SCHEMBL411178 | 0.65 | CRBN (1.00) | CYP1A2DDB1CRBNALDH1A1IKZF3 | |
| Thalidomide SCHEMBL7581 | 0.65 | CRBN (1.00) | CYP1A2DDB1CRBNALDH1A1IKZF3 | |
| Thalidomide SCHEMBL411175 | 0.65 | CRBN (1.00) | CYP1A2DDB1CRBNALDH1A1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3010501-B1 | ESTROGEN RECEPTOR MODULATOR AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2021-11-03 | — | — | EP | disclosed |
| EP-3303326-B1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-12-16 | — | — | EP | disclosed |
| EP-3233828-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-2791133-B1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3010502-B1 | AZETIDINE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2828243-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3303326-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| EP-2648726-B1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2018-04-04 | — | — | EP | disclosed |
| EP-3233828-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| WO-2012078805-A1 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012024620-A2 | AUTOTAXIN INHIBITORS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| WO-2011159550-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND USES THEREOF | AMIDRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011159769-A2 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011156518-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |